Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.67 |
| ▸ | GAA known ✓ | P10253 | 6/20 | 0.66 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.66 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31119219 | 1.00 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24412 | 0.98 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29357340 | 0.98 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL2972630 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL1223871 | 0.85 | KDM4E (0.70) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL7251305 | 0.85 | KDM4E (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL140666 | 0.83 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29433281 | 0.83 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL192100 | 0.82 | KDM4E (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29375113 | 0.82 | KDM4E (0.72) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073460-A1 | POLYETHER KETONE COMPOUND | AJINOMOTO CO., INC. (JP) | 2017-03-16 | — | — | US | disclosed |
| US-9458288-B2 | Polyester compound | AJINOMOTO CO., INC. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458289-B2 | Polyester compound | AJINOMOTO CO., INC. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20160237215-A1 | POLYAMIDE COMPOUND | AJINOMOTO CO., INC. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160024247-A1 | POLYESTER COMPOUND | AJINOMOTO CO., INC. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024248-A1 | POLYESTER COMPOUND | AJINOMOTO CO., INC. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20120095386-A9 | COMPOSITION AND DEVICE STRUCTURE FOR IONTOPHORESIS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8155738-B2 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20110021972-A1 | Composition and Device Structure For Iontophoresis | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-1442028-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040071765-A1 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| US-6673815-B2 | MODULATE BLOOD GLUCOSE LEVELS, TRIGLYCERIDE LEVELS, INSULIN LEVELS AND NON-ESTERIFIED FATTY ACID LEVELS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-06 | — | — | US | disclosed |
| US-20030130306-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2003040114-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1177813-A1 | IONTOPHORESIS DEVICE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1080731-A2 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021972-A1 | Composition and Device Structure For Iontophoresis | ASIC1, AQP1, PIEZO1 | CA2 725/4885GAA 3873/4885GLA 4171/4885 |
| US-20040071765-A1 | Composition and device structure for iontophoresis | ASIC1, AQP1, PIEZO1 | CA2 626/4885GAA 4038/4885GLA 3940/4885 |
| US-20030130306-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, GCGR | CA2 1297/4885GAA 13/4885GLA 138/4885 |
| US-20120095386-A9 | COMPOSITION AND DEVICE STRUCTURE FOR IONTOPHORESIS | ASIC1, AQP1, PIEZO1 | CA2 725/4885GAA 3873/4885GLA 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.